Table 2.
Summary of potential biomarkers of breast cancer progression by UPLC/MS analysis
| m/z | RT (min) | Metabolitea | Adductb | Related pathway | Contentc | |
|---|---|---|---|---|---|---|
| LC/NC | MT/LC | |||||
| 318.241 | 7.19989 | 9‐cis‐Retinoic acid | M + NH4 [1+] | Retinol metabolism | Down* | Down** |
| 176.066 | 0.89564 | l‐Dihydroorotic acid | M + NH4 [1+] | Pyrimidine metabolism | Up* | Up** |
| 274.092 | 4.90187 | Sphinganine | M + NH4 [1+] | Sphingolipid metabolism | Up* | Up** |
| 546.353 | 8.60841 | LysoPC(0:0/18:0) | M + Na [1+] | Glycerophospholipid metabolism | Up* | Up** |
| 459.248 | 7.43676 | LPA(18:1(9Z)/0:0) | M + Na [1+] | Glycerophospholipid metabolism | Up* | Up** |
| 487.280 | 8.81888 | SM(d18:0/16:1(9Z)) | M + H [1+] | Sphingolipid metabolism | Up* | Up** |
LC, localized breast cancer serum sample; LPA, lysophosphatidic acid; lysoPC, lysophosphatidylcholine; MT, metastatic breast cancer serum sample; m/z, mass‐to‐charge ratio; NC, normal control sample; RT, retention time; SM, sphingomyelin; UPLC/MS, ultra‐performance liquid chromatography/mass spectroscopy.
a
Metabolites formally identified by standard comparison.
b
Ionospheric models of mass spectrometry cationic scanning.
c
Comparison of characteristic metabolites’ integral peak area in the 3 groups.
Non‐parametric test was used for comparisons among the groups (*P < .05, **P < .01).